ABP 501 BIOSMILAR TO ADALIMUMAB: FINAL SAFETY, IMMUNOGENICITY, AND EFFICACY RESULTS FROM AN OPEN-LABEL EXTENSION STUDY

被引：7
|
作者：
Cohen, S. [1 ]
Pablos, J. L. [2 ]
Wang, H. [3 ]
Mueller, G. A. [4 ]
Kivitz, A. [5 ]
Matsumoto, A. [6 ]
Krishnan, E. [3 ]
机构：
[1] Metroplex Clin Res Ctr, Dallas, TX USA
[2] Inst Invest Hosp, Madrid, Spain
[3] Amgen Inc, Thousand Oaks, CA USA
[4] Abt Nephrol & Rheumatol, Gottingen, Germany
[5] Altoona Ctr Clin Res, Duncansville, PA USA
[6] Arthrit & Rheumatism Associates, Wheaton, IL USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.3288
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0171
引用
收藏
页码：834 / 835
页数：2
相关论文
共 50 条
  • [1] ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study
    Cohen, Stanley
    Pablos, Jose L.
    Zhang, Nan
    Rizzo, Warren
    Muller, Gerhard
    Padmanaban, Devi
    Kivitz, Alan
    Matsumoto, Alan K.
    Kaur, Primal
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [2] An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis
    Cohen, Stanley
    Pablos, Jose L.
    Pavelka, Karel
    Mueller, Gerard Anton
    Matsumoto, Alan
    Kivitz, Alan
    Wang, Hui
    Krishnan, Eswar
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [3] An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis
    Stanley Cohen
    Jose L. Pablos
    Karel Pavelka
    Gerard Anton Müller
    Alan Matsumoto
    Alan Kivitz
    Hui Wang
    Eswar Krishnan
    Arthritis Research & Therapy, 21
  • [4] LONG-TERM EFFICACY AND SAFETY OF LANADELUMAB: FINAL RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY
    Banerji, A.
    Hao, J.
    Yu, M.
    Bernstein, J.
    Johnston, D.
    Riedl, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S21 - S21
  • [5] Efficacy and Safety of ABP-450 (PrabotulinumtoxinA) in Adults With Cervical Dystonia: Results From the Open-label Extension of a Phase 2 Trial
    Jankovic, Joseph
    Oh, Chad
    Liu, Yan
    Abdul-Musawir, Najeebah
    Comella, Cynthia
    TOXICON, 2024, 237 : 36 - 37
  • [6] Long term efficacy and safety of ABP, 501 adalimumab biosimilar in inflammatory bowel diseases: preliminary results from the ADASWITCH study
    Cingolani, A.
    Felice, C.
    Lombardi, G.
    Onidi, F. M.
    Checchin, D.
    Colucci, R.
    Grossi, L.
    Ferronato, A.
    Rocchi, C.
    Ascolani, M.
    Binaghi, L.
    Dore, M. F.
    Fanini, L.
    Bulajic, M.
    Mocci, G.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I392 - I393
  • [7] Long term efficacy and safety of ABP, 501 adalimumab biosimilar in inflammatory bowel diseases: preliminary results from the ADASWITCH study
    Cingolani, A.
    Felice, C.
    Lombardi, G.
    Onidi, F. M.
    Checchin, D.
    Colucci, R.
    Grossi, L.
    Ferronato, A.
    Rocchi, C.
    Ascolani, M.
    Binaghi, L.
    Dore, M. F.
    Fanini, L.
    Bulajic, M.
    Mocci, G.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I392 - I393
  • [8] Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study
    Gleich, Gerald J.
    Roufosse, Florence
    Chupp, Geoffrey
    Faguer, Stanislas
    Walz, Bastian
    Reiter, Andreas
    Yancey, Steven W.
    Bentley, Jane H.
    Steinfeld, Jonathan
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (12): : 4431 - +
  • [9] MAINTENANCE OF EFFICACY, SAFETY AND TOLERABILITY OF ARMODAFINIL: AN OPEN-LABEL EXTENSION STUDY
    Black, J.
    Hull, S. G.
    Tiller, J.
    Yang, R.
    Harsh, J. R.
    SLEEP, 2009, 32 : A139 - A139
  • [10] Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study
    Steinfeld, J.
    Gleich, G. J.
    Roufosse, F.
    Chupp, G.
    Faguer, S.
    Reiter, A.
    Walz, B.
    Bentley, J. H.
    Bradford, E. S.
    Yancey, S. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
12345